Group 1: 华夏银行 Financial Performance - In Q3 2025, 华夏银行 reported operating revenue of 19.36 billion yuan, a year-on-year decrease of 15.02% [1][2] - The net profit attributable to shareholders was 6.51 billion yuan, an increase of 7.62% year-on-year [1][2] - For the first three quarters, the bank's operating revenue was 64.88 billion yuan, down 8.79% year-on-year, while net profit decreased by 2.86% to 17.98 billion yuan [1][2] Group 2: 华夏银行 Key Financial Ratios - Basic earnings per share remained stable at 0.38 yuan for Q3 and 1.04 yuan for the first three quarters [2] - The weighted average return on equity was 1.98% in Q3, down 0.12 percentage points year-on-year [3] - The total assets at the end of the reporting period were 4.586 trillion yuan, an increase of 4.80% from the end of the previous year [2] Group 3: 不良贷款和拨备情况 - The non-performing loan ratio was 1.58%, a decrease of 0.02 percentage points from the end of the previous year [3] - The provision coverage ratio was 149.33%, down 12.56 percentage points year-on-year [3] - The loan provision ratio was 2.36%, a decrease of 0.23 percentage points from the end of the previous year [3] Group 4: 华工科技 Financial Performance - 华工科技 reported Q3 2025 operating revenue of 3.41 billion yuan, a decrease of 10.33% year-on-year, while net profit increased by 31.15% to 410 million yuan [4][5] - For the first three quarters, the company achieved operating revenue of 11.04 billion yuan, a year-on-year increase of 22.62%, and net profit of 1.32 billion yuan, up 40.92% [4][5] Group 5: 汇川技术 Financial Performance - 汇川技术 reported operating revenue of 316.63 billion yuan for the first three quarters, a year-on-year increase of 24.67%, with net profit rising by 26.84% to 42.54 billion yuan [6][7] - In Q3, the company achieved operating revenue of 111.53 billion yuan, up 21.05% year-on-year, and net profit of 12.86 billion yuan, an increase of 4.04% [6][7] Group 6: 宝丰能源 Financial Performance - 宝丰能源 reported operating revenue of 355.45 billion yuan for the first three quarters, a year-on-year increase of 46.43%, with net profit rising by 97.27% to 89.5 billion yuan [8][9] - In Q3, the company achieved operating revenue of 127.25 billion yuan, up 72.49% year-on-year, and net profit of 32.32 billion yuan, an increase of 162.34% [8][9] Group 7: 生益科技 Performance Forecast - 生益科技 expects net profit for the first three quarters of 2025 to be between 2.42 billion and 2.46 billion yuan, representing a year-on-year increase of 76% to 79% [10] - The increase is attributed to higher sales of copper-clad laminates and improved product structure [10] Group 8: 巨化股份 Financial Performance - 巨化股份 reported Q3 2025 operating revenue of 70.62 billion yuan, a year-on-year increase of 21.22%, with net profit rising by 186.55% to 11.97 billion yuan [11] - For the first three quarters, the company achieved operating revenue of 203.94 billion yuan, up 13.89%, and net profit of 32.48 billion yuan, an increase of 160.22% [11] Group 9: 电投能源 Financial Performance - 电投能源 reported Q3 operating revenue of 79.39 billion yuan, a year-on-year increase of 3.34%, while net profit decreased by 8.52% to 13.31 billion yuan [21][22] - For the first three quarters, the company achieved operating revenue of 224.03 billion yuan, up 2.72%, and net profit decreased by 6.40% to 41.18 billion yuan [21][22]

Core Insights - The company reported a revenue of 2.674 billion yuan for the first three quarters of 2025, representing a year-on-year decline of 5.39% [1] - The net loss attributable to shareholders of the listed company was 21.387 million yuan [1] - The net loss attributable to shareholders after deducting non-recurring gains and losses was 66.7647 million yuan [1]

Core Insights - BGI Genomics (300676.SZ) reported a revenue of 2.674 billion yuan for the first three quarters of 2025, representing a year-on-year decline of 5.39% [1] - The company recorded a net loss attributable to shareholders of 21.387 million yuan [1] - The net loss attributable to shareholders, excluding non-recurring gains and losses, was 66.7647 million yuan [1]

Core Insights - BGI Genomics reported a decline in revenue and a negative net profit for the first three quarters of 2025 [1] Financial Performance - For the first three quarters, the company achieved a revenue of 2.674 billion yuan, a year-on-year decrease of 5.39% [1] - The net profit attributable to shareholders was -21.387 million yuan [1] - In the third quarter, the company generated a revenue of 1.042 billion yuan, reflecting a year-on-year growth of 9.19% [1] - However, the net profit for the third quarter was still negative at -27.1652 million yuan [1]

Core Viewpoint - The company aims to enhance its ability to manage foreign exchange risk and mitigate the impact of significant currency fluctuations on its performance by engaging in foreign exchange hedging activities in 2026 [1] Group 1: Foreign Exchange Hedging Strategy - The company and its subsidiaries plan to continue foreign exchange hedging activities with qualified financial institutions in 2026 [1] - The hedging products will include but are not limited to forward foreign exchange contracts, foreign exchange swaps, and foreign exchange options, or combinations of these products [1] - The maximum contract value held on any trading day is expected to not exceed RMB 1 billion or its equivalent in foreign currency [1] Group 2: Authorization and Validity - The authorization for the hedging activities will be valid for a period of 12 months, from January 1, 2026, to December 31, 2026 [1] - The authorized amount can be used in a rolling manner within the specified period [1]

Core Viewpoint - BGI Genomics announced the approval of a proposal for its wholly-owned subsidiary to jointly apply for a technology project with related parties, involving a related transaction [1] Group 1 - The fourth meeting of the fourth board of directors and the seventh meeting of the fourth supervisory board were held on October 23, 2025 [1] - The proposal was approved with the related director Wang Jian abstaining from the vote [1]

Core Viewpoint - The rapid identification of pathogens has become a critical component of public health prevention and clinical diagnosis, prompting the company to initiate a collaborative project aimed at developing a specialized pathogen detection system [1] Group 1: Project Overview - The company’s subsidiary, Tianjin BGI Medical Testing Co., Ltd., plans to jointly apply for a national science and technology major project focused on the development of a convenient long-read sequencing system for pathogen detection [1] - The total funding for the joint application project is 120 million yuan, with 20 million yuan requested from the national budget and 100 million yuan to be self-funded by the participating institutions [1] - Among the self-funded amount, Tianjin BGI Medical Testing Co., Ltd. will contribute 50 million yuan [1] Group 2: Project Participation - Tianjin BGI Medical Testing Co., Ltd. will participate in three specific topics within the project, focusing on the development of pathogen single-molecule detection kits, supporting algorithms, databases, and research on automation applications [1]

华大基因10月23日晚间公告，2025年第三季度实现营业收入10.42亿元，同比增长9.19%；归属于上市公 司股东的净利润亏损2716.52万元，上年同期净亏损1.43亿元；基本每股收益亏损0.0653元。前三季度实 现营业收入26.74亿元，同比下降5.39%；归属于上市公司股东的净利润亏损2138.7万元，上年同期净亏 损1.24亿元；基本每股收益亏损0.0514元。 ...

Core Viewpoint - BGI Genomics (300676) reported a revenue of 1.042 billion yuan in Q3 2025, marking a year-on-year increase of 9.19%, while the net profit attributable to shareholders was a loss of 27.1652 million yuan, compared to a loss of 142 million yuan in the same period last year [1] Summary by Sections Financial Performance - In Q3 2025, the company achieved a revenue of 1.042 billion yuan, reflecting a 9.19% increase year-on-year [1] - The net profit attributable to shareholders for Q3 2025 was a loss of 27.1652 million yuan, an improvement from a loss of 142 million yuan in Q3 2024 [1] - For the first three quarters of 2025, the total revenue was 2.674 billion yuan, which represents a year-on-year decline of 5.39% [1] - The net profit attributable to shareholders for the first three quarters of 2025 was a loss of 21.387 million yuan, compared to a loss of 124 million yuan in the same period last year [1]

第一条 为规范深圳华大基因股份有限公司（以下简称公司或本公司）董事、 高级管理人员的离职管理，保障公司治理稳定性及股东合法权益，根据《中华 人民共和国公司法》（以下简称《公司法》）、《上市公司章程指引》等法律、 法规、规范性文件及《深圳华大基因股份有限公司章程》（以下简称《公司章 程》）的有关规定，制定本制度。 深圳华大基因股份有限公司 董事、高级管理人员离职管理制度 深圳华大基因股份有限公司 董事、高级管理人员离职管理制度 第一章 总则 第三条 董事可以在任期届满以前提出辞任。董事辞任应向公司提交书面辞 职报告，公司收到辞职报告之日起辞任生效，公司将在两个交易日内披露有关 情况。高级管理人员辞职的，自董事会收到辞职报告时生效。 除存在本制度第七条规定情形外，出现下列规定情形的，在改选出的董事就 任前，原董事仍应当按照有关法律法规、《深圳证券交易所上市公司自律监管指 引第 2 号——创业板上市公司规范运作（2025 年修订）》、深圳证券交易所其 他规定和公司章程的规定继续履行职责： （一）董事任期届满未及时改选，或者董事在任期内辞任导致董事会成员低 于法定最低人数； （二）审计委员会成员辞任导致审计委员会成员 ...